12.82
-0.48(-3.61%)
Currency In USD
| Previous Close | 13.3 |
| Open | 13.41 |
| Day High | 13.41 |
| Day Low | 12.82 |
| 52-Week High | 32 |
| 52-Week Low | 7.65 |
| Volume | 32,141 |
| Average Volume | 77,779 |
| Market Cap | 246.29M |
| PE | -0.53 |
| EPS | -24.26 |
| Moving Average 50 Days | 11.02 |
| Moving Average 200 Days | 11.39 |
| Change | -0.48 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $37.95 as of September 13, 2025 at a share price of $12.82. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $82.92 as of September 13, 2025 at a share price of $12.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lye
Lyell Immunopharma Announces Participation in September Investor Conferences
GlobeNewswire Inc.
Sep 02, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer,
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
GlobeNewswire Inc.
Jul 25, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a sec